LIVE
REGN
Regeneron Pharmaceuticals, Inc. · Health Care - Biotechnology
$609.94
-3.23% this month
VERSUS
⟷
COMPARE
VRTX
Vertex Pharmaceuticals Incorporated · Health Care - Biotechnology
$451.63
+3.99% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
REGN
3
VRTX
2
Comparison scoreboard
REGN LEADS 3/5AI Score
REGN 42.1
VRTX ✓50.5
1Y Return
REGN ✓+19.86%
VRTX +2.18%
Fwd P/E
REGN ✓11.34
VRTX 21.03
Target Up.
REGN ✓+36.62%
VRTX +21.49%
Op. Margin
REGN 20.66%
VRTX ✓38.13%
Metrics last refreshed: 6/22/2026
Quick take
REGN vs VRTX Stock Comparison: AI Score, Valuation, Performance and Upside
Both REGN and VRTX are elite large-cap biotechs with dominant, high-profit franchise drugs and strong internal R&D capabilities. Regeneron's Dupixent offers broader commercial reach across common inflammatory diseases, while Vertex's CF monopoly generates exceptional profit margins from a specialized rare disease franchise — both are compounding profitable biotech investments.
REGN vs VRTX compares two of biotech's premier large-cap franchises: Regeneron's Dupixent-led inflammatory disease platform versus Vertex's near-monopoly cystic fibrosis franchise.
Live analysis · updated 6/22/2026
REGN holds the edge across 3 of 5 key metrics in this comparison. REGN leads on both 1-year return (+19.86%) and forward P/E (11.34x vs 21.03x for VRTX), a relatively favorable combination of momentum and valuation. On fundamentals, REGN is growing revenue faster (19.00%), while VRTX maintains the higher operating margin (38.13%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+36.62%) than for VRTX (+21.49%).
Normalized 1Y performance
REGN
VRTX
Recent returns
REGN
VRTX
Analyst price targets & sentiment
REGN · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$535.00
analyst high$950.00
analyst mean$833.31
current price$609.94
+36.6% upside to analyst mean
VRTX · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.1/5.0)
Price target range
analyst low$330.00
analyst high$621.00
analyst mean$548.69
current price$451.63
+21.5% upside to analyst mean
Who should consider this stock?
REGN may suit investors who:
- →Want exposure to a large-cap biotech with a commercially proven, multi-indication blockbuster in Dupixent
- →Value Regeneron's track record of internal drug discovery and commercialization across multiple products
- →Believe Dupixent's continued indication expansion can sustain its revenue growth trajectory
VRTX may suit investors who:
- →Want exposure to a large-cap biotech with exceptional profitability from a near-monopoly CF franchise
- →Believe suzetrigine non-opioid pain represents a significant new commercial opportunity
- →Value Vertex's strong free cash flow generation enabling pipeline investment without dilution
Performance & AI score
| Metric | REGN | VRTX |
|---|---|---|
| AI score | 42.1 | 50.5 |
| AI rank | #882 | #443 |
| Latest close | $609.94 | $451.63 |
| 1M return | -3.23% | +3.99% |
| 6M return | -18.65% | +0.47% |
| 1Y return | +19.86% | +2.18% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | REGN | VRTX |
|---|---|---|
| 1Y ago | $11.88K (+18.8%) started 2025-06-18 | $10.07K (+0.7%) started 2025-06-18 |
| 5Y ago | $11.46K (+14.6%) started 2021-06-21 | $24.06K (+140.6%) started 2021-06-21 |
| 10Y ago | $17.37K (+73.7%) started 2016-06-20 | $52.08K (+420.8%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | REGN | VRTX |
|---|---|---|
| Market cap | $63.95B | $114.63B |
| Trailing P/E | 14.88 | 26.80 |
| Forward P/E | 11.34 | 21.03 |
| Price/Sales | 3.78 | 10.42 |
| EV/Revenue | 3.75 | 8.95 |
| Analyst target | $833.31 | $548.69 |
| Target upside | +36.62% | +21.49% |
Growth, profitability & risk
| Metric | REGN | VRTX |
|---|---|---|
| Revenue growth | 19.00% | 7.80% |
| Earnings growth | -7.20% | 61.40% |
| EPS growth | -7.20% | +61.40% |
| FCF margin | +21.94% | +22.78% |
| Operating margin | 20.66% | 38.13% |
| Profit margin | 29.65% | 35.51% |
| ROIC proxy | 14.55% | 24.20% |
| Return on equity | 14.55% | 24.20% |
| Dividend yield | 0.62% | N/A |
| Beta | 0.24 | 0.31 |
| Debt/equity | 8.61 | 10.26 |
| Current ratio | 3.56 | 3.02 |
| Quick ratio | 2.84 | 2.38 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
REGN max drawdown26.05%
VRTX max drawdown23.56%
REGN max wkly drop12.87%
VRTX max wkly drop20.71%
5Y risk snapshot
REGN max drawdown59.69%
VRTX max drawdown29.07%
REGN max wkly drop20.21%
VRTX max wkly drop20.71%
10Y risk snapshot
REGN max drawdown59.69%
VRTX max drawdown41.60%
REGN max wkly drop20.21%
VRTX max wkly drop22.29%
Performance metrics by period
| Period | Metric | REGN | VRTX |
|---|---|---|---|
| 1Y | Growth | +18.76% | +0.72% |
| CAGR | +18.79% | +0.72% | |
| Sharpe ratio | 0.55 | 0.07 | |
| Max drawdown | 26.05% | 23.56% | |
| Max daily drop | 9.82% | 20.60% | |
| Max wkly drop | 12.87% | 20.71% | |
| 5Y | Growth | +14.48% | +140.61% |
| CAGR | +2.75% | +19.23% | |
| Sharpe ratio | 0.10 | 0.61 | |
| Max drawdown | 59.69% | 29.07% | |
| Max daily drop | 19.01% | 20.60% | |
| Max wkly drop | 20.21% | 20.71% | |
| 10Y | Growth | +73.43% | +420.79% |
| CAGR | +5.66% | +17.95% | |
| Sharpe ratio | 0.19 | 0.53 | |
| Max drawdown | 59.69% | 41.60% | |
| Max daily drop | 19.01% | 20.70% | |
| Max wkly drop | 20.21% | 22.29% |
Business comparison
| Category | REGN | VRTX |
|---|---|---|
| Company | Regeneron Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Regeneron is a large-cap biotechnology company known for its blockbuster drugs Dupixent (atopic dermatitis, asthma) and Eylea (wet AMD), with a broad pipeline including antibody-based therapies, bispecific antibodies, and gene editing approaches. | Vertex is a large-cap biotechnology company that has established a near-monopoly in cystic fibrosis (CF) treatments with its Trikafta/Kaftrio franchise, generating substantial profits while expanding into pain, kidney disease, and cell therapy through CRISPR-based approaches. |
| Investor focus | Investors track Dupixent's continued revenue growth across its expanding indications, Eylea's defense against biosimilar competition, and the advancement of next-generation products in the pipeline. | Investors track Vertex's CF franchise durability and patient uptake, progress of pipeline programs in non-opioid pain (suzetrigine), kidney disease (inaxaplin), and its CRISPR-based gene therapy collaboration with CRISPR Therapeutics. |
REGN strengths
- →Dupixent is one of the best-selling drugs globally with continued growth driven by new indications in atopic dermatitis, asthma, COPD, and beyond
- →Strong internal drug discovery capabilities with a track record of bringing multiple successful drugs to market
- →Eylea (aflibercept) remains a leading treatment for retinal diseases despite biosimilar entry
VRTX strengths
- →Near-monopoly position in cystic fibrosis treatment with Trikafta generating billions in highly profitable revenue
- →Strong free cash flow from CF franchise funds pipeline expansion without capital market dependency
- →Non-opioid pain drug (suzetrigine) represents a potential major new franchise outside CF
Risks to watch — REGN
- →Eylea is facing increasing biosimilar competition that will pressure its revenue over time
- →Dupixent will eventually face biosimilar competition as its patents approach expiration
- →Continued pipeline investment is critical to sustaining growth as current franchise products mature
Risks to watch — VRTX
- →CF franchise is highly concentrated in a rare disease with a finite patient population that is gradually being addressed
- →Suzetrigine pain franchise faces a long commercial build and competition from existing pain management approaches
- →Gene therapy programs remain high-risk and early-stage despite significant investment
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →